Abstract
The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.
Publication types
-
Comparative Study
-
English Abstract
-
Review
MeSH terms
-
Adalimumab
-
Amyloidosis / drug therapy
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / pharmacology
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Psoriatic / drug therapy
-
Autoimmune Diseases / drug therapy*
-
Behcet Syndrome / drug therapy
-
Crohn Disease / drug therapy
-
Etanercept
-
Female
-
Hepatitis C / drug therapy
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / pharmacology
-
Immunoglobulin G / therapeutic use*
-
Inflammation / drug therapy
-
Infliximab
-
Liver Cirrhosis / drug therapy
-
Off-Label Use
-
Pain / drug therapy
-
Pregnancy
-
Pregnancy Complications / drug therapy
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Receptors, Tumor Necrosis Factor, Type II / antagonists & inhibitors
-
Rheumatic Diseases / drug therapy*
-
Spondylitis, Ankylosing / drug therapy
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Receptors, Tumor Necrosis Factor, Type II
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept